Search 

The Almac Group is an established contract development and manufacturing organisation that provides the most unique range of integrated drug development services available to the pharmaceutical & biotech industry.

We are a privately owned organisation that has organically grown over 50 years and now employs in excess of 5,000 high skilled personnel. Almac is headquartered in Craigavon, Northern Ireland with 17 global facilities across Europe, USA and Asia.

Our quality, innovation and efficiency are testament to the fact that over 600 companies worldwide trust Almac for their Chemical, Pharmaceutical and Clinical Development needs.

Addressing the increasing pressure for Biopharma companies to bring their clinical candidates through their pipeline faster, more efficiently and at a lower cost, Almac provides an integrated CMC service, bridging the gap between drug substance and drug product development.

As an established provider of both drug substance (advanced intermediates and Active Pharmaceutical Ingredients – small molecules and peptides) and drug product development services, and by offering these within an integrated package, our client partners are assured of scientific continuity from a dedicated project team, resulting in significant savings in both time and costs.

Clinical Accelerator is an independent European clinical trial management organisation offering a range of clinical research and patient enrolment support services to worldwide clients in the pharmaceutical, biotechnology and medical device industries.

We are specialists in effective and timely patient recruitment, and commit to achieving patient enrolment targets within fixed timelines.

Placing clinical trials in our Eastern European countries of operation allows Clinical Accelerator to achieve significant cost savings for our clients. Fast and large-scale patient recruitment is another important advantage. To ensure excellent quality of our Eastern European trials, we carefully select sites and investigators able to work to the highest quality standards with full ICH GCP compliance.

Clinical Accelerator provides client-tailored services. We are always prepared to adjust our system and procedures to the requirements of virtual, small and medium-sized biotech sponsors or larger pharma companies. We take a proactive role in the management of our projects based on intensive communication with our sponsors and joint commitment to success and always take responsibility for delivering clinical trials to agreed timeframes and within agreed budgets.

We deliver affordable clinical trials solutions with quality and speed!

Our vision is to employ new dual-acting retinoic acid receptor modulators (RAR-M) as the basis for developing a new rational effective treatment approach for ALS and meet that unmet need. In the longer term, we see a great opportunity to use our IP from the ALS arena to move on to target the wider range of neurodegenerative diseases. 

Viramal is a Specialty Pharmaceutical Company developing a portfolio of therapies in the fields of male & female sexual health focussing on the utilisation and application of sex steroid hormones.

Viramal’s patent protected technology platform facilitates superior drug delivery both transdermally and to sensitive female reproductive areas with an outstanding safety profile. Similar to cosmetic creams, Viramal’s products have excellent patient acceptability, and unlike competitors does not require alcohol for API solubility or absorption enhancement. All of the Company’s products benefit from the avoidance of the First Hepatic Pass, and the safety/ metabolite concerns that result other marketed products, particularly in Menopausal Hormone Therapy.